Kornimate/medical-research-clean huggingface dataset:
integrated colonoscopy improvement program in italy

Conditions: Colon Lesion; Colon Polyp

Summary: the italian society of digestive endoscopy (sied) and the italian association of gastroenterologists and hospital digestive endoscopists (aigo) want to develop an effective training program for endoscopists to improve the quality of colonoscopies through careful evaluation of quality indicators and how they can be improved with an appropriate educational program. primary objective of this study is to evaluate the variation of "polyp detection rate (pdr) and adenoma detection rate (adr)" obtained by operators at high and low volume of colonoscopy before and after a training period. secondary objectives are to compare high and low volume endoscopists' performance before and after training comparing by evaluation of withdrawal time; number polyps / patient and number adenomas / patient; the percentage and time of intubation of the cecum, ; patient's pain perception based on the nurse assessed patient comfort score (napcoms) scale. the study is structured as follow: * a first phase when all endoscopists collect the results of 200 colonoscopies in an electronic case report form (ecrf) is formed(maximum enrollment period 4 months). * a second phase of training through an e-platform in which the endoscopists are offered with an online refresh reviewing the international standard parameters to perform a quality colonoscopy. once the final training exam have been passed, the endoscopist will be able to access the third phase * a third phase in which the endoscopists will collect prospectively the colonoscopies they perform in an ecrf (maximum enrollment period 4 months).


Eligibility criteria:
inclusion criteria: * patients between 50 and 75 years old * colonoscopy for cancer screening program, post polypectomy follow up, patients with abdominal symptoms suggestive for colonic pathology. exclusion criteria: * patients aged \ 75 yrs * presence of alarm symptoms * american society of anesthesiologists (asa) classification ≥ 3 * presence of colonic stenosis * previous colonic resection * presence of diverticulitis * history of inflammatory bowel disease (ibd) * history of polyposis syndrome * pregnancy or breastfeeding * inability to provide informed consent * severe cardiovascular illness * contraindication to undergo to sedation * anticoagulant therapy * melanosis coli
a prospective longitudinal mixed study on the change track of sleep quality in critically ill children

Conditions: Critical Illness; Child; Sleep Disorder

Summary: this research adopts the uniform parallel hybrid research design; the quantitative data and qualitative data were collected at the same time, and then the quantitative and qualitative data were analyzed respectively. finally, the two data sets were combined. comprehensive interpretation of the study issues through complementarity and mutual validation of quantitative and qualitative data.

with the progress and development of medical technology, the mortality rate of critically ill children continues to decline. to improve the long-term prognosis of children has become a new goal of modern medicine. sleep disorders in critically ill children are caused by disease factors, the complex environment of icu, and various treatment factors, which have seriously affected the patient's rehabilitation and long-term quality of life. attention should be paid to the sleep disorders in critically ill children. at present, the research on sleep disorders in critically ill patients in china is mostly focused on adults, and the critically ill children are rarely involved, and there is no research related to sleep disorders and recovery tracks of critically ill children. this prospective longitudinal mixed study aims to describe the change trajectory of sleep disorder and recovery in critically ill children and provide suggestions for subsequent clinical workers to formulate reasonable intervention measures.

Eligibility criteria:
inclusion criteria: ① age 3-12 years; * children who are conscious during icu, * children with glasgow score of 15 exclusion criteria: * (1) did not meet the discharge standards, and asked to be discharged; * children with sleep disorder before admission to picu, that is, those with baseline cshq score \> 41; * the child had a history of mental illness and cognitive impairment. * children with brain injury, coma, disturbance of consciousness, epilepsy and status epilepticus, obstructive sleep apnea hypopnea syndrome; ⑤ children with hearing and hearing impairment ⑥icu stay \> 30 days.
impact of hemodialysis on plasma carnitine levels in patients with end stage renal disease

Conditions: Hemodialysis Complication

Summary: objectives * to assess the levels of plasma carnitine in controls and hemodialysis patients. * to give supplementary l-carnitine to study subjects for a duration of 5months. * to compare the values of plasma carnitine before and after l carnitine supplementation. * to assess the role of carnitine supplementation on biochemical and clinical parameters.

.abstract introduction dialysis therapy can cause a decrease in both free carnitine and plasma acyl carnitines after only six months of dialysis treatment. a positive correlation between ac/fc ratio and months on hd therapy has been reported. we investigate in this study the role of oral l-carnitine supplementation on anemia, blood pressure, cardiac dysfunction and muscle cramps in hemodialysis patients. objectives * to assess the levels of plasma carnitine in controls and hemodialysis patients. * to give supplementary l-carnitine to study subjects for a duration of 5months. * to compare the values of plasma carnitine before and after l carnitine supplementation. * to assess the role of carnitine supplementation on biochemical and clinical parameters. study design and setting: it will be a case-control study, which will be conducted in the department of biochemistry, university of karachi in collaboration with nephrology ward of jpmc, karachi in a period of one year after approval of synopsis. method: total 120 subjects will be included in this study which will be divided into two groups. group a will comprise of 60 subjects of chronic renal failure who will be the control group. group b will comprise of 60 subjects who will be on hemodialysis for more than 1 year. blood samples will be taken after informed consent. group b subjects will be given l-carnitine supplementation for five months under strict monitoring. physical, biochemical and clinical parameters of group b subjects will be compared before and after supplementation. results: data will be analyzed using spss version 21. results will be shared after completion of research. conclusion: conclusion will be shared after completion of research.

Eligibility criteria:
inclusion criteria: • individuals of either sex (male and female). * the study included people between the ages of 18 and 50 who had had dialysis for more than two years without taking additional antioxidants. exclusion criteria: * • individuals with any other chronic ailment, such as cancer or tuberculosis. * patients with acute renal failure who are receiving hemodialysis. * all subjects who refused to take part in the investigation.

Keywords: hemodialysis l-carnitine chronic kidney disease
study to evaluate panobinostat (daci) pharmacokinetics and safety in solid tumors and varying renal function

Conditions: Advanced Solid Tumors

Summary: panobinostat (lbh589) is a deacetylase inhibitor (daci) which belongs to a structurally novel cinnamic hydroxamic acid class of compounds. it is one of the most potent class i/ii pan-dac inhibitor (pan-daci) that has shown anti-tumor activity in pre-clinical models and patients with solid tumors and hematological malignancies. to date, the pharmacokinetics (pk) of panobinostat has been characterized in patients with solid tumors and hematological malignancies participating in several phase i/ii clinical studies. panobinostat pk does not appear to be different in patients with solid tumors and hematological malignancies. however, the effect of organ dysfunction on pk of panobinostat is yet to be elucidated. kidney and liver are involved in the elimination and metabolism of panobinostat. the current study is designed to evaluate the impact of renal function status on panobinostat pk.


Eligibility criteria:
inclusion criteria: 1. patient has documented diagnosis of advanced solid tumor for which no standard systemic therapy exists 2. patient has normal or abnormal renal organ function 3. patient has provided written informed consent prior to any screening procedures exclusion criteria: 1. patient needing valproic acid for any medical condition during the study or within 5 days prior to the first panobinostat dose 2. patient received prior treatment with dac inhibitors including panobinostat 3. patient requiring dialysis 4. patient requiring diuretics unless patient is taking potassium sparring diuretics 5. patient has acute renal failure, history of transplant, esrd (however acceptable severe renal impaired group) 6. female patient who is pregnant or breast feeding or with childbearing potential and not willing to use a double method of contraception up to 3 months after the end of study treatment. male patient who is not willing to use a barrier method of contraception up to 3 months after the end of study treatment. other protocol-defined inclusion/exclusion criteria may apply

Keywords: ph i panobinostat (daci) pk & safety solid tumors varying renal function advanced
improving glycaemic control with l-carnitine

Conditions: Type 2 Diabetes

Summary: a characteristic of type 2 diabetes is a high blood glucose level, which is partly caused by the inability of insulin to stimulate glucose uptake into our muscles (insulin resistance). insulin resistance can be caused by the accumulation of fat within muscle of overweight individuals. the aim of the present research is to test whether a novel nutritional intervention containing l-carnitine can increase the amount of carnitine within muscle of individuals recently diagnosed with type 2 diabetes. carnitine is essential for 'burning fat' within our muscles and it is hoped that increasing the amount of carnitine within muscle can increase fat burning, lower muscle fat, reverse insulin resistance and ultimately lower blood glucose levels and wellbeing. we also aim to investigate the cellular mechanisms underlying any observed effects in a hope to identify further targets to lower muscle fat.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) 27-37 kg/m2 * male * age 18-60 years old * type 2 diabetes mellitus reasonably well controlled (hba1c less than or equal to 58 mmol/mol) on diet therapy or metformin alone * not taking anti-diabetes medication other than metformin * understand verbal and/or written explanation of the study requirements exclusion criteria: * malignancy (excluding localised basal and squamous cell skin cancer) * metabolic diseases (stable treated hypothyroidism allowed) * active cardiovascular disease (current angina, myocardial infarct, or coronary artery surgery/angioplasty within 12 months) * primary muscle disorders * cerebrovascular disease * neurological disease e.g. epilepsy, parkinsons disease * active respiratory disease * active gastrointestinal or liver disease * renal impairment (egfr \<60 ml/min) * clotting dysfunction * anti-diabetes medication other than metformin * other medications that may affect glucose tolerance (e.g. corticosteroids), muscle metabolism, or safety (e.g. anticoagulants) * any other conditions in addition to the above that the investigators consider may affect study measurements or safety
mesalamine in environmental enteropathy

Conditions: Malnutrition

Summary: undernutrition is one of the most important health issues in kenya. children who are chronically undernourished do not reach their full potential and are at increased risk of infectious disease. stunting occurs in a third of kenyan children and has severe and long-term consequences in terms of health, development, and poverty. several studies have shown that stunting is frequently associated with subclinical inflammation of the bowel, a condition referred to as environmental enteropathy (ee), previously known as 'tropical sprue' or 'tropical enteropathy'. ee is clinically similar to childhood inflammatory bowel diseases (ibd), including crohn's disease. the treatment of ibd routinely involves provision of gut immunomodulatory agents, but this approach has never been tried in ee. this proposal outlines a pilot double-blind randomised placebo-controlled trial of mesalamine (also called mesalazine - the safest immunomodulator used in ibd with least systemic activity) in treatment of severely malnourished children with ee.


Eligibility criteria:
inclusion criteria: * children aged 1 to 5 years old. * provision of informed consent by parent or guardian. * stunting (height for age z score \<-2) * severe malnutrition (one or more of mid-upper arm circumference \<11.5cm, weight for height z score \<-3, or nutritional oedema). * eligible for outpatient management of malnutrition (i.e. no evidence of acute infection, and passes 'appetite test' according to national guidelines). * evidence of chronic inflammation (elevated erythrocyte sedimentation rate, esr \>20mm/hr). exclusion criteria: * known hiv disease or tuberculosis. * known previous renal disease or asthma. * known allergy or hypersensitivity to mesalamine, other salicylate drugs, or any of the product ingredients. * biochemical evidence of acute renal or hepatic impairment on screening blood tests. * thrombocytopenia * recent (previous two weeks) bloody diarrhoea. * concurrent medication known to interact with the study drug (non-steroidal anti-inflammatory drugs, ranitidine, proton-pump inhibitors) * acute infection requiring treatment, e.g. lower respiratory tract infection or febrile illness. * other reason at the discretion of the attending clinician (independent of the trial team).
exploring pathogenesis and treatment of hypercalcemia caused by intramuscular injection of paraffinoil

Conditions: Hypercalcemia; Renal Injury; Paraffinoma

Summary: the aim of the study is to characterize paraffin oil induced granulomatous disease. we will investigate pathogenesis and natural history of paraffin disease. subsequently, through further translational studies, we intend to identify novel treatments to be tested in future randomized clinical trials.


Eligibility criteria:
inclusion criteria: * previous intramuscular injection of paraffin or other oil exclusion criteria: * none
the effect of education on patient care outcomes in individuals with diabetic foot ulcer

Conditions: Foot Ulcer, Diabetic; Patient Engagement; Self Efficacy; Wound Healing; Nursing

Summary: the aim of this study is to determine the effect of social cognitive learning theory-based education on patient participation, self-efficacy and wound healing in individuals with diabetic foot ulcers. the research was conducted with 52 patients (25 intervention and 27 control) with wagner 2 diabetic foot ulcers at gülhane training and research hospital between january and september 2024.

the study was conducted in four stages: first application to the clinic, 1st month, 2nd month and 3rd month. while the social cognitive learning theory was applied to the intervention group, only the currrent clinical education was provided to the control group. the research data were collected using the "data collection form regarding participants' identifying characteristics", "diabetic foot information form", "metabolic status and wound follow-up form", "patient participation scale" and "diabetic foot care self-efficacy scale". the results of this study show that education based on social cognitive learning theory is effective on patient participation, self-efficacy and wound healing in individuals with diabetic foot ulcers.

Eligibility criteria:
inclusion criteria: * individuals 18 years of age or older agree to participate in the study have type 2 diabetes have a wagner classification score of 2 have the same wound care protocols (epidermal growth factor/hyalunoric acid containing cream and dressing with gauze) exclusion criteria: * having communication difficulties and mental retardation having vision and manual dexterity problems having diabetic foot infection

Keywords: diabetic foot ulcer patient participation self-efficacy wound healing nursing
efficacy of adjuvant cytokine-induced killer cells in colon cancer

Conditions: Colonic Neoplasms

Summary: it has been reported that the immune status of patients with cancer were suppressed, especially those after surgery and adjuvant chemotherapy. thus, immunotherapy may decrease the recurrence rate after surgery. cik cells transfusion has been reported as an effect therapy in advanced cancers. in another retrospective study, investigators found that adjuvant cik therapy would prolong the disease-free survival (dfs) for colorectal cancer patients. the purpose of this study is to determine wether adjuvant immunotherapy with cik cells in patients with colon cancer after operation will prolong dfs, and overall survival (os).


Eligibility criteria:
inclusion criteria: * colon cancer in stage iii or stage ii with high risk after r0 resection * eastern cooperative oncology group (ecog) performance status was 0 - 1; * life expectancy of at least 3 months; * normal bone marrow, liver, renal, heart and lung function; * age between 18-80; * patients who provided written informed consent for this study exclusion criteria: * with uncontrolled other malignant tumors; * with uncontrolled infection or tubercle bacillus (tb) or underlying diseases that were severe or life threatening; * patients who need to treat with radiotherapy; * patients who accepted other immunotherapy * with sever mental disease or disease with central nervous system (cns); * with the history of organ transplantation, including bone marrow transplantation or stem cell transplantation; * patients with auto immune diseases; * pregnant or lactating.

Keywords: colon cancer cytokine-induced killer cells adjuvant immunotherapy adjuvant chemotherapy
dietary cholesterol and defects in cholesterol synthesis in mevalonate kinase deficiency

Conditions: Mevalonic Aciduria; Mevalonate Kinase Deficiency; Immune System Diseases; Periodic Fever Syndromes, Hereditary; Lipid Metabolism, Inborn Errors

Summary: participants wanted for study of mevalonate kinase deficiency (mkd), mevalonic aciduria, or hyperimmunoglobulinemia with periodic fever syndrome (hids). patients with mkd (mevalonic aciduria or hyperimmunoglobulinemia with periodic fever syndrome (hids)) may be eligible for a research study conducted at oregon health \& science university (ohsu) in portland, oregon usa. the purpose of the study is to find out more about how these diseases affect body chemistry and health. the researchers also want to find out how cholesterol in the diet affect blood cholesterol and how the body handles cholesterol. this is a short-term and long-term dietary study. the long-term goal of this research is to see if controlling dietary cholesterol can decrease any of the symptoms of the diseases. the study could involve up to 12 one-week admissions to ohsu over the course of 5 years.

participants are admitted to the clinical research center for up to a week per visit. additional visits at least yearly encouraged. during the week we measure such things as cholesterol absorption, sterol and bile acid synthesis, mevalonate and mevalonate shunt products, isoprenoids, fatty acids, leukotrienes, plasma cholesterol and other sterol levels. also, the effects of altering dietary cholesterol on plasma 24-s oh-cholesterol, a measure of brain cholesterol turnover, will be evaluated. studies of body composition/ metabolism/ growth, development, behavior, sleep, feeding, hearing and vision will be carried out to document the phenotype and determine if dietary intervention may be helpful. the objective of the study is to characterize the metabolic and phenotypic consequences of mkd and study the effects of altering dietary cholesterol in mkd. we hypothesize that some of the phenotypic effects of mkd are due to altered cholesterol metabolism, but that the phenotype is predominantly due to derangements in isoprenoid metabolism.

Eligibility criteria:
inclusion criteria: * must have documented mevalonate kinase deficiency, mevalonic aciduria, or hids * must be willing to participate in most research procedures exclusion criteria: * unable or unwilling to participate in most research procedures

Keywords: cholesterol defects mevalonic aciduria mevalonate kinase deficiency hids hyperimmunoglobulinemia with periodic fever syndrome mkd lipid metabolism, inborn errors periodic fever syndromes, hereditary mevalonic acid mevalonate kinase cholesterol, dietary hyper igd multiple malformations fever
hpmpc (cidofovir) peripheral cmv retinitis trial protocol

Conditions: Cytomegalovirus Retinitis; HIV Infections

Summary: to evaluate short-term and long-term safety and efficacy of intravenous cidofovir (hpmpc) for treatment of small peripheral cytomegalovirus (cmv) retinitis lesions. to provide data on the relative safety and efficacy of 2 doses of hpmpc as maintenance regimens.

in stage 1, up to 30 patients are randomized to either observation with deferral of treatment until the retinitis progresses (observation group), or to intravenous hpmpc at the higher dose for two consecutive weekly induction doses, followed by the lower dose every other week for maintenance. in stage 2, up to 70 patients are randomized to observation or to hpmpc at the higher dose for two consecutive weekly induction doses followed by either dose every other week for maintenance, for a total of three treatment groups. concomitant saline hydration and probenecid are administered to patients receiving hpmpc.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * oral trimethoprim/sulfamethoxazole. * aerosolized pentamidine. * dapsone. * fluconazole. * ketoconazole. * itraconazole. * rifabutin. * filgrastim (g-csf). * antiretroviral agents. patients must have: * aids by cdc criteria. * cmv retinitis as determined by a soca-certified ophthalmologist, with lesion size, location, and severity as specified in the disease status field. prior medication: allowed: * prophylaxis with anti-cmv agents. exclusion criteria concurrent medication: excluded: * ongoing therapy for cmv disease with ganciclovir, foscarnet, cmv hyperimmune immunoglobulin, or other investigational agents with anti-cmv activity. * therapy with nephrotoxic drugs, including amphotericin b, aminoglycoside antibiotics, vidarabine, and intravenous pentamidine. patients with the following prior conditions are excluded: * history of renal disease or renal dialysis. * history of clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia. * history of clinically significant probenecid allergy. prior medication: excluded: * prior therapy for cmv disease with ganciclovir, foscarnet, cmv hyperimmune immunoglobulin, or other investigational agents with anti-cmv activity. * therapy with nephrotoxic drugs within the past 7 days, including amphotericin b, aminoglycoside antibiotics, vidarabine, and intravenous pentamidine. drug or alcohol abuse sufficient to hinder compliance with study.

Keywords: retinitis cytomegalovirus infections acquired immunodeficiency syndrome antiviral agents cidofovir